COMPARATIVE EFFICACY OF VONOPRAZAN AND PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION BASED ON CLARITHROMYCIN SUSCEPTIBILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i9.55714Keywords:
Helicobacter pylori, Vonoprazan, Proton-pump inhibitor, Clarithromycin resistance, Meta-analysisAbstract
Objectives: Due to the rising burden of Helicobacter pylori-resistant strains, specifically to clarithromycin (CAM), there is a decline in eradication rates (ERs) with proton-pump inhibitors (PPI) containing regimens. Vonoprazan (VPZ), a first-in-class potassium-competitive acid blocker, has a rapid onset, and longer, more profound acid suppression than PPIs. This systematic review and meta-analysis aims to evaluate the efficacy of VPZ versus PPI-based triple therapy in eradicating H. pylori based on clarithromycin susceptibility.
Methods: A systematic search was performed using relevant MeSH terms in PubMed, Cochrane, Web of Science, and Google Scholar databases for studies comparing the efficacy of VPZ and PPI triple therapies in eradicating H. pylori, with results stratified by clarithromycin susceptibility. Studies meeting the inclusion criteria were included, and data were extracted. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Random effects model was applied in all analyses.
Results: Eight potentially eligible studies were included. Among patients with clarithromycin-resistant H. pylori strains, VPZ-triple therapy showed significant superiority to PPI-triple therapy in both randomized controlled trials (RCT) (pooled ER-75.0% vs. 49.0%; OR-3.28; 95% CI 1.62–6.66; p=0.001) and non-RCT (NRCT) (ER-82.0% vs. 42.0%; OR-4.98; 95% CI, 2.47–10.03; p<0.001) studies. For eradication of clarithromycin susceptible (CAM-S) strains in RCTs, VPZ therapy showed significant superiority over PPI therapies (ER-90.0% vs. 86.0%; OR-1.42; 95% CI, 1.02–1.98; p=0.038); however, there was no significant difference between the therapies seen in NRCTs (ER-89.0% vs. 86.0%; OR-4.30; 95% CI, 0.72–25.85; p=0.111).
Conclusion: VPZ triple therapy is superior to the conventional PPI triple therapy in eradicating CAM-resistant H. pylori strains. For CAM-S H. pylori infection, VPZ is comparable to PPI triple therapy.
Downloads
References
1. Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023 Apr 20;9(1):19. doi: 10.1038/s41572-023-00431-8, PMID 37081005, PMCID PMC11558793
2. Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024 Apr;166(4):605-19. doi: 10.1053/j.gastro.2023.12.022. Erratum in: Gastroenterology. 2025 Apr;168(4):850. doi: 10.1053/j. gastro.2025.01.008, PMID 39891636
3. Morad Kasani S, Mofid M, Navidifar T, Golab N, Parvizi E, Badmasti F, et al. Insights into Helicobacter pylori macrolide resistance: A comprehensive systematic review and meta-analysis. Front Microbiol. 2024 Oct 30;15:1481763. doi: 10.3389/fmicb.2024.1481763, PMID 39539713, PMCID PMC11557415
4. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-27. doi: 10.1016/ S1473-3099(17)30753-3, PMID 29276051
5. Sukri A, Hanafiah A, Yusoff H, Shamsul Nizam NA, Nameyrra Z, Wong Z, et al. Multidrug-resistant Helicobacter pylori strains: A five-year surveillance study and its genome characteristics. Antibiotics (Basel). 2022 Oct 11;11(10):1391. doi: 10.3390/antibiotics11101391, PMID 36290049, PMCID PMC9598532
6. Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 2016 Jul 19;5:F1000 Faculty Rev-1747. doi: 10.12688/f1000research.8598.1, PMID 30023042, PMCID PMC4957631
7. Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3- ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011 Nov;339(2):412-20. doi: 10.1124/jpet.111.185314, PMID 21828261, PMCID PMC3199995
8. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757, PMID 20525969
9. Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016 May;43(10):1048-59. doi: 10.1111/apt.13588, PMID 26991399
10. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: A systematic review. Pharmacotherapy. 2003 Apr;23(4):460-71. doi: 10.1592/phco.23.4.460.32128, PMID 12680476
11. Padwale V, Kirnake V, Daswani R, Kodmalwar A, Gupta A. A comprehensive review on the efficacy and safety of vonoprazan in the management of gastric acid-related diseases. Cureus. 2024 Jul 17;16(7):e64777. doi: 10.7759/cureus.64777, PMID 39156336, PMCID PMC11330167
12. Pavani Y, Aravind S, Annam C, Subba Rao M. Quantification and quality control of triple-drug combination employed for gastric ulcer using stability-indicating selective Rp-HPLC technique. Int J App Pharm. 2024 May 7;16(3):140-8. doi: 10.22159/ijap.2024v16i3.50320
13. Anusha K, Sowjanya G. A reliable RP-UPLC-TUV method for simultaneous estimation of clarithromycin, amoxicillin, and vonoprazan in co-packed pharmaceutical dosage forms: Method development and validation with stability indicating properties. Int J App Pharm. 2024 Mar 7;16(2):351-7. doi: 10.22159/ijap.2024v16i2.50059
14. Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eadication: A meta-analysis of randomized clinical trials. BioMed Res Int. 2019 May 9;2019:9781212. doi: 10.1155/2019/9781212, PMID 31211144, PMCID PMC6532346
15. Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 2017 Jan 28;23(4):668-75. doi: 10.3748/wjg.v23.i4.668, PMID 28216974, PMCID PMC5292341
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71, PMID 33782057, PMCID PMC8005924
17. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898, PMID 31462531
18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603-5. doi: 10.1007/s10654-010- 9491-z, PMID 20652370
19. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology. 2022 Sep;163(3):608-19. doi: 10.1053/j. gastro.2022.05.055, PMID 35679950
20. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304, PMID 26935876, PMCID PMC5036253
21. Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018 Apr;23(2):e12456. doi: 10.1111/hel.12456, PMID 29271026
22. Tamaki H, Noda T, Morita M, Omura A, Kubo A, Ogawa C, et al. 437 - an open- label, multi-center, randomized, superiority trial of vonoprazan versus esomeprazole as part of first-line triple therapy for Helicobacter pylori infection. Gastroenterology. 2019;156(6):S-89. doi: 10.1016/S0016-5085(19)37010-6
23. Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, et al. Clinical trial: Seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022 Aug;56(3):436-49. doi: 10.1111/ apt.17070, PMID 35665947
24. Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: A prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med. 2017;56(11):1277-85. doi: 10.2169/ internalmedicine.56.7833, PMID 28566587, PMCID PMC5498188
25. Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: The effect of clarithromycin resistance. Dig Dis Sci. 2016 Nov;61(11):3215-20. doi: 10.1007/ s10620-016-4305-0, PMID 27659671
26. Noda H, Noguchi S, Yoshimine T, Goji S, Adachi K, Tamura Y, et al. A novel potassium-competitive acid blocker improves the efficacy ofclarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016 Sep;25(3):283-8. doi: 10.15403/ jgld.2014.1121.253.7hp, PMID 27689190
27. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997 Jan;39(1):5-12. doi: 10.1093/jac/39.1.5, PMID 9044021
28. Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020 Jan 15;59(2):153-61. doi: 10.2169/internalmedicine.2521-18, 2019 Jun 27. PMID 31243237, PMCID PMC7008041
29. Salehi N, Attaran B, Zare-Mirakabad F, Ghadiri B, Esmaeili M, Shakaram M, et al. The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains. Helicobacter. 2020 Dec;25(6):e12731. doi: 10.1111/hel.12731, PMID 32794288
30. Xia HX, Fan XG, Talley NJ. Clarithromycin resistance in Helicobacter pylori and its clinical relevance. World J Gastroenterol. 1999 Jun;5(3):263-6. doi: 10.3748/wjg.v5.i3.263, PMID 11819443, PMCID PMC4688482
31. Fallone CA, Chiba N, Van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006, PMID 27102658
32. Rocha GR, Lemos FF, Silva LG, Luz MS, Correa Santos GL, Rocha Pinheiro SL, et al. Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches. World J Gastroenterol. 2025 Mar 14;31(10):102289. doi: 10.3748/wjg.v31. i10.102289, PMID 40093672, PMCID PMC11886534
33. Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, et al. Role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for Helicobacter pylori eradication in the clinical setting. Antibiotics (Basel). 2021 Feb 21;10(2):214. doi: 10.3390/antibiotics10020214, PMID 33669969, PMCID PMC7924850
34. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003 Jan;17(1):99-109. doi: 10.1046/j.1365- 2036.2003.01396.x, PMID 12492738
35. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter. 2017 Dec;22(6): e12438. doi: 10.1111/hel.12438, PMID 28884937
36. Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018 Aug;23(4):e12495. doi: 10.1111/hel.12495. Erratum in: Helicobacter. 2021 Aug;26(4):e12829. doi: 10.1111/hel.12829, PMID 34318975
37. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017 Jul;46(2):106-14. doi: 10.1111/apt.14130, PMID 28497487
Published
How to Cite
Issue
Section
Copyright (c) 2025 Dr. Sheethal Srenigarajan, V.P. Karthik, Sowmya Parvathareddy, Kavitha Ramasamy
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
